7 research outputs found
Large Genomic Imbalances in Brugada Syndrome
Purpose Brugada syndrome (BrS) is a form of cardiac arrhythmia which may lead to sudden cardiac death. The recommended genetic testing (direct sequencing of SCN5A) uncovers disease-causing SNVs and/or indels in ~20% of cases. Limited information exists about the frequency of copy number variants (CNVs) in SCN5A in BrS patients, and the role of CNVs in BrS-minor genes is a completely unexplored field. Methods 220 BrS patients with negative genetic results were studied to detect CNVs in SCN5A. 63 cases were also screened for CNVs in BrS-minor genes. Studies were performed by Multiplex ligation-dependent probe amplification or Next-Generation Sequencing (NGS). Results The detection rate for CNVs in SCN5A was 0.45% (1/220). The detected imbalance consisted of a duplication from exon 15 to exon 28, and could potentially explain the BrS phenotype. No CNVs were found in BrS-minor genes. Conclusion CNVs in current BrS-related genes are uncommon among BrS patients. However, as these rearrangements may underlie a portion of cases and they undergo unnoticed by traditional sequencing, an appealing alternative to conventional studies in these patients could be targeted NGS, including in a single experiment the study of SNVs, indels and CNVs in all the known BrS-related genes
Detecció de Copy Number Variants mitjançant seqüenciació d'alt rendiment en la Mort Sobtada CardÃaca heredità ria
Arrhythmogenic cardiac diseases are the main cause of SCD among the population under 35 years of age. Despite the improvements in genetic diagnosis, the percentage of cases that remain unexplained after genetic analysis is still high. Several studies have identified CNVs as causative of cardiac diseases associated with SCD, but exhaustive analysis of multiple genes in large cohorts of patients has never been performed for most SCD-related diseases. In this thesis a CNV detection algorithm has been developed for the analysis of high-throughput sequencing data of the clinically relevant genomic regions associated with SCD and related diseases. Through the optimization of the capture probe designs we have been able to sequence samples that exhibit high quality and coverage homogeneity throughout all sequenced regions. These samples allowed the development of the CNV detection algorithm, specifically designed for this type of samples, which has shown a high sensitivity, specificity and precision.Les malalties cardÃaques arritmogèniques suposen la principal causa de MSC entre la població menor de 35 anys. Tot i les millores en el diagnòstic genètic, el percentatge de casos sense causa després de l'anà lisi genètica és elevat. Diversos estudis associen les CNVs com les causants de malalties cardÃaques associades a MSC. Però encara no s’ha realitzat mai el cribratge exhaustiu d’un grup important de gens en una gran cohort de pacients diagnosticats amb aquestes malalties. En aquesta tesi s’ha desenvolupat un algoritme de detecció de CNVs per l’anà lisi de dades provinents de la seqüenciació d’alt rendiment de les regions clÃnicament rellevants associades a la MSC i a les malalties relacionades. Optimitzant els dissenys de sondes de captura s’han seqüenciat unes mostres d’alta qualitat i d’elevada homogeneïtat de cobertura. Aquestes permeten la posada a punt d’un l’algoritme de detecció de CNVs que ha demostrat una alta sensibilitat, especificitat i precisió
Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome
Background
The use of next-generation sequencing enables a rapid analysis of many genes associated
with sudden cardiac death in diseases like Brugada Syndrome. Genetic variation is identified
and associated with 30–35% of cases of Brugada Syndrome, with nearly 20–25%
attributable to variants in SCN5A, meaning many cases remain undiagnosed genetically.
To evaluate the role of genetic variants in arrhythmogenic diseases and the utility of nextgeneration
sequencing, we applied this technology to resequence 28 main genes associated
with arrhythmogenic disorders.
Materials and Methods
A cohort of 45 clinically diagnosed Brugada Syndrome patients classified as SCN5Anegative
was analyzed using next generation sequencing. Twenty-eight genes were resequenced:
AKAP9, ANK2, CACNA1C, CACNB2, CASQ2, CAV3, DSC2, DSG2, DSP,
GPD1L, HCN4, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNQ1,
NOS1AP, PKP2, RYR2, SCN1B, SCN3B, SCN4B, SCN5A, SNTA1, and TMEM43. A total of
85 clinically evaluated relatives were also genetically analyzed to ascertain familial
segregation.
Results and Discussion
Twenty-two patients carried 30 rare genetic variants in 12 genes, only 4 of which were previously
associated with Brugada Syndrome. Neither insertion/deletion nor copy number variation
were detected. We identified genetic variants in novel candidate genes potentially
associated to Brugada Syndrome. These include: 4 genetic variations in AKAP9 including a de novo genetic variation in 3 positive cases; 5 genetic variations in ANK2 detected in 4 cases; variations in KCNJ2 together with CASQ2 in 1 case; genetic variations in RYR2,
including a de novo genetic variation and desmosomal proteins encoding genes including
DSG2, DSP and JUP, detected in 3 of the cases. Larger gene panels or whole exome
sequencing should be considered to identify novel genes associated to Brugada Syndrome.
However, application of approaches such as whole exome sequencing would difficult the
interpretation for clinical purposes due to the large amount of data generated. The identification
of these genetic variants opens new perspectives on the implications of genetic background
in the arrhythmogenic substrate for research purposes.
Conclusions
As a paradigm for other arrhythmogenic diseases and for unexplained sudden death, our
data show that clinical genetic diagnosis is justified in a family perspective for confirmation
of genetic causality. In the era of personalized medicine using high-throughput tools, clinical
decision-making is increasingly comple
Identification of genetic alterations, as causative genetic defects in long qt syndrome, using next generation sequencing technology
Background: Long QT Syndrome is an inherited channelopathy leading to sudden cardiac death due to ventricular arrhythmias. Despite that several genes have been associated with the disease, nearly 20% of cases remain without an identified genetic cause. Other genetic alterations such as copy number variations have been recently related to Long QT Syndrome. Our aim was to take advantage of current genetic technologies in a family affected by Long QT Syndrome in order to identify the cause of the disease. Methods: Complete clinical evaluation was performed in all family members. In the index case, a Next Generation Sequencing custom-built panel, including 55 sudden cardiac death-related genes, was used both for detection of sequence and copy number variants. Next Generation Sequencing variants were confirmed by Sanger method. Copy number variations variants were confirmed by Multiplex Ligation dependent Probe Amplification method and at the mRNA level. Confirmed variants and copy number variations identified in the index case were also analyzed in relatives. Results: In the index case, Next Generation Sequencing revealed a novel variant in TTN and a large deletion in KCNQ1, involving exons 7 and 8. Both variants were confirmed by alternative techniques. The mother and the brother of the index case were also affected by Long QT Syndrome, and family cosegregation was observed for the KCNQ1 deletion, but not for the TTN variant. Conclusions: Next Generation Sequencing technology allows a comprehensive genetic analysis of arrhythmogenic diseases. We report a copy number variation identified using Next Generation Sequencing analysis in Long QT Syndrome. Clinical and familiar correlation is crucial to elucidate the role of genetic variants identified to distinguish the pathogenic ones from genetic nois
A novel variant in RyR2 causes familiar catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia is a rare familial arrhythmogenic disease. It usually occurs in juvenile patients with a structurally normal heart and causes exercise–emotion triggered syncope and sudden cardiac death. The main gene associated with catecholaminergic polymorphic ventricular tachycardia is RyR2, encoding the cardiac ryanodine receptor protein which is involved in calcium homeostasis. After the identification of a 16 year-old man presenting with exercise-induced sudden cardiac death, clinically diagnosed as catecholaminergic polymorphic ventricular tachycardia, we collected the family information and performed a comprehensive genetic analysis using Next Generation Sequencing technology. The initial electrocardiogram in the emergency department revealed ventricular fibrillation. On electrocardiogram monitoring, sinus tachycardia degenerated into bidirectional ventricular and into ventricular fibrillation. Catecholaminergic polymorphic ventricular tachycardia was clinically diagnosed in 5 of the 14 family members evaluated. There were no additional reports of seizures, pregnancy loss, neonatal death, or sudden cardiac death in family members. Genetic analysis of the index case identified only one rare novel variant p.Ile11Ser (c.32T > G) in the RyR2 gene. Subsequent familial analysis identified segregation of the genetic variant with the disease. All current evidence supports that novel p.Ile11Ser variant in the RyR2 gene is a potential disease-causing variant in catecholaminergic polymorphic ventricular tachycardia. To our knowledge, there has been no previous case report of catecholaminergic polymorphic ventricular tachycardia associated to this missense varian
Large Genomic Imbalances in Brugada Syndrome
PURPOSE: Brugada syndrome (BrS) is a form of cardiac arrhythmia which may lead to sudden cardiac death. The recommended genetic testing (direct sequencing of SCN5A) uncovers disease-causing SNVs and/or indels in ~20% of cases. Limited information exists about the frequency of copy number variants (CNVs) in SCN5A in BrS patients, and the role of CNVs in BrS-minor genes is a completely unexplored field. METHODS: 220 BrS patients with negative genetic results were studied to detect CNVs in SCN5A. 63 cases were also screened for CNVs in BrS-minor genes. Studies were performed by Multiplex ligation-dependent probe amplification or Next-Generation Sequencing (NGS). RESULTS: The detection rate for CNVs in SCN5A was 0.45% (1/220). The detected imbalance consisted of a duplication from exon 15 to exon 28, and could potentially explain the BrS phenotype. No CNVs were found in BrS-minor genes. CONCLUSION: CNVs in current BrS-related genes are uncommon among BrS patients. However, as these rearrangements may underlie a portion of cases and they undergo unnoticed by traditional sequencing, an appealing alternative to conventional studies in these patients could be targeted NGS, including in a single experiment the study of SNVs, indels and CNVs in all the known BrS-related gene
Large Genomic Imbalances in Brugada Syndrome
Purpose Brugada syndrome (BrS) is a form of cardiac arrhythmia which may lead to sudden cardiac death. The recommended genetic testing (direct sequencing of SCN5A) uncovers disease-causing SNVs and/or indels in ~20% of cases. Limited information exists about the frequency of copy number variants (CNVs) in SCN5A in BrS patients, and the role of CNVs in BrS-minor genes is a completely unexplored field. Methods 220 BrS patients with negative genetic results were studied to detect CNVs in SCN5A. 63 cases were also screened for CNVs in BrS-minor genes. Studies were performed by Multiplex ligation-dependent probe amplification or Next-Generation Sequencing (NGS). Results The detection rate for CNVs in SCN5A was 0.45% (1/220). The detected imbalance consisted of a duplication from exon 15 to exon 28, and could potentially explain the BrS phenotype. No CNVs were found in BrS-minor genes. Conclusion CNVs in current BrS-related genes are uncommon among BrS patients. However, as these rearrangements may underlie a portion of cases and they undergo unnoticed by traditional sequencing, an appealing alternative to conventional studies in these patients could be targeted NGS, including in a single experiment the study of SNVs, indels and CNVs in all the known BrS-related genes